Universitair Ziekenhuis Brussel - Academic Profile

Publications

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert , Jacob Schachter , Georgina V. Long +19 more

The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced mela...

2015 New England Journal of Medicine 5661 citations

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Jeffrey S. Weber , Sandra P. D’Angelo , David R. Minor +25 more

2015 The Lancet Oncology 2617 citations

Affiliated Researchers

Bart Neyns

Universitair Ziekenhuis Brussel

Institution Info

Type: healthcare
Country: BE
Publications: 2
Citations: 8,278

External Links

Identifiers

ROR: https://ror.org/038f7y939